JOURNAL BROWSE
Search
Advanced SearchSearch Tips
Association of the -2518 A/G Polymorphism of MCP-1 with Breast Cancer in Punjab, North-West India
facebook(new window)  Pirnt(new window) E-mail(new window) Excel Download
 Title & Authors
Association of the -2518 A/G Polymorphism of MCP-1 with Breast Cancer in Punjab, North-West India
Sambyal, Vasudha; Guleria, Kamlesh; Kapahi, Ruhi; Manjari, Mridu; Sudan, Meena; Uppal, Manjit Singh; Singh, Neeti Rajan;
  PDF(new window)
 Abstract
Background: Monocyte chemoattractant protein-1 (MCP-1) is a major chemokine thought to be responsible for monocyte and T-lymphocyte recruitment in acute inflammatory conditions and recruitment of macrophages in tumors. It is also implicated in cardiovascular disease, rheumatoid arthritis and chronic obstructive pulmonary disease. The aim of the present study was to investigate the correlation between MCP-1 -2518 A/G polymorphism and breast cancer risk in patients from Amritsar city of Punjab state in North-West India. Materials and Methods: We screened DNA samples of 200 sporadic breast cancer patients and 200 age and gender matched unrelated healthy individuals for MCP-1 -2518 A/G polymorphism using the PCR-RFLP method. Results: A significantly increased frequency of the GG genotype was observed in patients as compared to controls. Individuals carrying the MCP1 -2518GG genotype had a two fold risk for breast cancer (OR
 Keywords
Breast cancer;polymorphism;MCP-1;chemokine;risk factor;
 Language
English
 Cited by
1.
Decreased Serum Monocyte Chemoattractant Protein-1 in Salivary Gland Tumor Patients,;;;;;

Asian Pacific Journal of Cancer Prevention, 2016. vol.17. 7, pp.3601-3604 crossref(new window)
1.
The association of genetic variants in chemokine genes with the risk of psoriasis vulgaris in Chinese population, Medicine, 2017, 96, 46, e8283  crossref(new windwow)
 References
1.
Adeli K, Ogbonna G (1990). Rapid purification of human DNA from whole blood for potential application in clinical chemistry laboratories. Clin Chem, 36, 261-4.

2.
Amann B, Perabo FG, Wirger A, Hugenschmidt H, Schultze-Seemann W (1998). Urinary levels of monocyte chemoattractant protein-1 correlate with tumour stage and grade in patients with bladder cancer. Br J Urol, 82, 118-21. crossref(new window)

3.
Arenberg DA, Keane MP, DiGiovine B, et al (2000). Macrophage infiltration in human non-small-cell lung cancer: the role of CC chemokines. Cancer Immunol Immunother, 49, 63-70. crossref(new window)

4.
Attar R, Agachan B, Kuran SB, et al (2010). Association of CCL2 and CCR2 gene variants with endometrial cancer in Turkish women. In Vivo, 24, 243-8.

5.
Baggiolini M (1998). Chemokines and leukocyte traffic. Nature, 392, 565-8. crossref(new window)

6.
Balkwill F, Mantovani A (2001). Inflammation and cancer: back to Virchow? Lancet, 357, 539-45. crossref(new window)

7.
Bektas-Kayhan K, Unur M, Boy-Metin Z, Cakmakoglu B (2012). MCP-1 and CCR2 gene variants in oral squamous cell carcinoma. Oral Dis, 18, 55-9. crossref(new window)

8.
Buraczynska M, Bednarek-Skublewska A, Buraczynska K, Ksiazek A (2008). Monocyte chemoattractant protein-1 (MCP-1) gene polymorphism as a potential risk factor for cardiovascular disease in hemodialyzed patients. Cytokine, 44, 361-5. crossref(new window)

9.
Conti I, Rollins BJ (2004). CCL2 (monocyte chemoattractant protein-1) and cancer. Semin Cancer Biol, 14, 149-54. crossref(new window)

10.
Craig MJ, Loberg RD (2006). CCL2 (Monocyte Chemoattractant Protein-1) in cancer bone metastases. Cancer Metastasis Rev, 25, 611-9.

11.
Da LS, Zhang Y, Zhang S, et al (2013). Association between MCP-1 -2518A/G polymorphism and cancer risk: evidence from 19 case-control studies. PLoS One, 8, 82855. crossref(new window)

12.
Ghilardi G, Biondi ML, La Torre A, Battaglioli L, Scorza R (2005). Breast cancer progression and host polymorphisms in the chemokine system: role of the macrophage chemoattractant protein-1 (MCP-1) -2518 G allele. Clin Chem, 51, 452-5. crossref(new window)

13.
Gu H, Ni M, Guo X, et al (2011). The functional polymorphism in monocyte chemoattractant protein-1 gene increases susceptibility to gastric cancer. Med Oncol, 28, 280-5. crossref(new window)

14.
Hanahan D, Weinberg RA (2000). The hallmarks of cancer. Cell, 100, 57-70. crossref(new window)

15.
Jia LQ, Shen YC, Guo SJ, et al (2013). The 2518 A/G polymorphism in the MCP-1 gene and cancer risk: a metaanalysis. Asian Pac J Cancer Prev, 14, 3575-9. crossref(new window)

16.
Joshi NN, Bhat S, Hake S, Kale M, Kannan S (2014). Opposing effects of pro- and anti-inflammatory cytokine gene polymorphisms on the risk for breast cancer in western Indian women: a pilot study. Int J Immunogenet, 41, 242-9. crossref(new window)

17.
Katakami N, Matsuhisa M, Kaneto H, et al (2010). Monocyte chemoattractant protein-1 (MCP-1) gene polymorphism as a potential risk factor for diabetic retinopathy in Japanese patients with type 2 diabetes. Diabetes Res Clin Pract, 89, 9-12. crossref(new window)

18.
Kruszyna L, Lianeri M, Rubis B, et al (2011). CCL2 -2518 A/G single nucleotide polymorphism as a risk factor for breast cancer. Mol Biol Rep, 38, 1263-7. crossref(new window)

19.
Kucukgergin C, Isman FK, Cakmakoglu B, Sanli O, Seckin S (2012). Association of polymorphisms in MCP-1, CCR2 and CCR5 genes with the risk and clinicopathological characteristics of prostate cancer. DNA Cell Biol, 31, 1418-24. crossref(new window)

20.
Kucukgergin C, Isman FK, Dasdemir S, et al (2012). The role of chemokine and chemokine receptor gene variants on the susceptibility and clinicopathological characteristics of bladder cancer. Gene, 511, 7-11. crossref(new window)

21.
Landi S, Gemignani F, Bottari F, et al (2006). Polymorphisms within inflammatory genes and colorectal cancer. J Negat Results Biomed, 5, 15. crossref(new window)

22.
Li L, Zhang J, Weng X, Wen G (2015). Genetic variations in monocyte chemoattractant protein-1 and susceptibility to ovarian cancer. Tumor Biol, 36, 233-8. crossref(new window)

23.
Li M, Knight DA, A Snyder L, Smyth MJ, Stewart TJ (2013). A role for CCL2 in both tumor progression and immunosurveillance. Oncoimmunology, 2, 25474. crossref(new window)

24.
Li YW, Yang CQ, Xiao YL, et al (2015). The -A2518G polymorphism in the MCP-1 gene and inflammatory bowel disease risk: A meta-analysis. J Dig Dis, 16, 177-85. crossref(new window)

25.
Liu GX, Zhang X, Li S, Koiiche RD, Sindsceii JH, Song H (2013). Monocyte chemotactic protein-1 and CC chemokine receptor 2 polymorphisms and prognosis of renal cell carcinoma. Tumor Biol, 34, 2741-6. crossref(new window)

26.
Mandal RK, Agrawal T, Mittal RD (2015). Genetic variants of chemokine CCL2 and chemokine receptor CCR2 genes and risk of prostate cancer. Tumor Biol, 36, 375-81. crossref(new window)

27.
Mantovani A, Allavena P, Sica A, Balkwill F (2008). Cancerrelated inflammation. Nature, 454, 436-44. crossref(new window)

28.
Moon JY, Jeong L, Lee S, et al (2007). Association of polymorphisms in monocyte chemoattractant protein-1 promoter with diabetic kidney failure in Korean patients with type 2 diabetes mellitus. J Korean Med Sci, 22, 810-4. crossref(new window)

29.
Moriya R, Takahashi K, Kitahara A, et al (2014). Possible involvement of PI3K-dependent pathways in the increased VEGF120 release from osteoblastic cells preloaded with palmitate in vitro. Biochem Biophys Res Commun, 445, 275-81. crossref(new window)

30.
Nahon P, Sutton A, Rufat P, et al (2008). Chemokine system polymorphisms, survival and hepatocellular carcinoma occurrence in patients with hepatitis virus-related cirrhosis. World J Gastroenterol, 14, 713-9. crossref(new window)

31.
Narter KF, Agachan B, Sozen S, Cincin ZB, Isbir T (2010). CCR2-64I is a risk factor for development of bladder cancer. Genet Mol Res, 9, 685-92. crossref(new window)

32.
Navratilova Z (2006). Polymorphisms in CCL2&CCL5 chemokines/chemokine receptors genes and their association with diseases. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub, 150, 191-204. crossref(new window)

33.
Negus RP, Stamp GW, Relf MG, et al (1995). The detection and localization of monocyte chemoattractant protein-1 (MCP-1) in human ovarian cancer. J Clin Invest, 95, 2391-6. crossref(new window)

34.
Ohta M, Kitadai Y, Tanaka S, et al (2002). Monocyte chemoattractant protein-1 expression correlates with macrophage infiltration and tumor vascularity inhuman esophageal squamous cell carcinomas. Int J Cancer, 102, 220-4. crossref(new window)

35.
Polyak K (2011). Heterogeneity in breast cancer. J Clin Invest, 121, 3786-8. crossref(new window)

36.
Riethdorf L, Riethdorf S, Gutzlaff K, Prall F, Loning T (1996). Differential expression of the monocyte chemoattractant protein-1 gene in human papillomavirus-16-infected squamous intraepithelial lesions and squamous cell carcinomas of the cervix uteri. Am J Pathol, 149, 1469-76.

37.
Rovin BH, Lu L, Saxena R (1999). A novel polymorphism in the MCP-1 gene regulatory region that influences MCP-1 expression. Biochem Biophys Res Commun, 259, 344-8. crossref(new window)

38.
Saenz-Lopez P, Carretero R, Co'zar JM, et al (2008). Genetic polymorphisms of RANTES, IL1-A, MCP-1 and TNF-A genes in patients with prostate cancer. BMC Cancer, 8, 382. crossref(new window)

39.
Saji H, Koike M, Yamori T, et al (2001). Significant correlation of monocyte chemoattractant protein 1 expression with neovascularization and progression of breast carcinoma. Cancer, 92, 1085-91. crossref(new window)

40.
Singh V, Srivastava P, Srivastava N, Kapoor R, Mittal RD (2012). Association of inflammatory chemokine gene CCL2I/D with bladder cancer risk in North Indian population. Mol Biol Rep, 39, 9827-34. crossref(new window)

41.
Soria G, Ben-Baruch A (2008). The inflammatory chemokines CCL2 and CCL5 in breast cancer. Cancer Lett, 267, 271-85. crossref(new window)

42.
Taylor JG, Choi EH, Foster CB, Chanock SJ (2001). Using genetic variation to study human disease. Trends Mol Med, 7, 507-12. crossref(new window)

43.
Tse KP, Tsang NM, Chen KD, et al (2007). MCP1 Promoter Polymorphism at 2518 is associated with metastasis of nasopharyngeal carcinoma after treatment. Clin Cancer Res, 13, 6320-6. crossref(new window)

44.
Ueno T, Toi M, Saji H, et al (2000). Significance of macrophage chemoattractant protein-1 in macrophage recruitment, angiogenesis, and survival in human breast cancer. Clin Cancer Res, 6, 3282-9.

45.
Valkovic T, Lucin K, Krstulja M, Dobi-Babic R, Jonjic N (1998). Expression of monocyte chemotactic protein-1 in human invasive ductal breast cancer. Pathol Res Pract, 194, 335-40. crossref(new window)

46.
Van Coillie E, Van Damme J, Opdenakker G (1999). The MCP/ eotaxin subfamily of CC chemokines. Cytokine Growth Factor Rev, 10, 61-86. crossref(new window)

47.
Vazquez-Lavista LG, Lima G, Gabilondo F, Llorente L (2009). Genetic association of monocyte chemoattractant protein 1 (MCP-1)-2518 polymorphism in Mexican patients with transitional cell carcinoma of the bladder. Urology, 74, 414-8. crossref(new window)

48.
Wei X, Tian Y, Lu W, et al (2015). Functional polymorphisms in monocyte chemoattractant protein-1 are associated with increased susceptibility to ovarian cancer. DNA Cell Biol, 34, 37-42. crossref(new window)

49.
Wu HH, Lee TH, Tee YT, et al (2013). Relationships of single nucleotide polymorphisms of monocyte chemoattractant protein 1and chemokine receptor 2 with susceptibility and clinicopathologic characteristics of neoplasia of uterine cervix in Taiwan women. Reprod Sci, 20, 1175-83. crossref(new window)

50.
Yang L, Shi GL, Song CX, Xu SF (2010). Relationship between genetic polymorphism of MCP-1 and non-small-cell lung cancer in the Han nationality of North China. Genet Mol Res, 9, 765-71. crossref(new window)

51.
Yeh CB, Tsai HT, Chen YC, et al (2010). Genetic polymorphism of CCR2-64I increased the susceptibility of hepatocellular carcinoma. J Surg Oncol, 102, 264-70. crossref(new window)

52.
Yoshie O, Imai T, Nomiyama H (2001). Chemokines in immunity. Adv Immunol, 78, 57-110. crossref(new window)

53.
Yoshimura T, Yuhki N, Moore SK, et al (1989). Human monocyte chemoattractant protein-1 (MCP-1). Full-length cDNA cloning, expression in mitogen-stimulated blood mononuclear leukocytes, and sequence similarity to mouse competence gene JE. FEBS Lett, 244, 487-93. crossref(new window)

54.
Zirn B, Samans B, Spangenberg C, et al (2005). All-trans retinoic acid treatment of Wilms tumor cells reverses expression of genes associated with high risk and relapse in vivo. Oncogene, 24, 5246-51. crossref(new window)